Status:
COMPLETED
Evaluation of Postmortem Pulmonary Interstitial Fibrosis Severity and EGFR Positivity in Covid-19 Pneumonia
Lead Sponsor:
Bursa Yuksek Ihtisas Training and Research Hospital
Conditions:
Pneumonia, Viral
COVID-19 Pneumonia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim of this study is to examine the relationship between the severity of fibrosis in the lung tissue and EGFR positivity in patients who died due to covid-19 pneumonia, with the demographic charac...
Detailed Description
The pathophysiology of Covid 19 infection still remains complex. Diffuse alveolo-interstitial damage, organizing pneumonia and severe fibrotic organizing pneumonia have been reported and possibly asso...
Eligibility Criteria
Inclusion
- \> 18 years old
- Patients who died while lying in the Intensive Care Unit with the diagnosis of Covid-19 pneumonia
Exclusion
- \<18 years old
- Patients who were treated with the diagnosis of Covid 19 pneumonia and recovered
Key Trial Info
Start Date :
August 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT05290441
Start Date
August 15 2021
End Date
December 1 2022
Last Update
February 6 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Bursa Yüksek İhtisas EAH
Bursa, Eyalet/Yerleşke, Turkey (Türkiye), 16115
2
Seyhan Dülger
Bursa, Yıldırım, Turkey (Türkiye), 16115